B46 Zygomycosis

Name of the Condition

• Zygomycosis
• ICD-10 Code: B46

Summary

Zygomycosis is a rare but aggressive fungal infection caused by organisms in the order Mucorales. It primarily affects individuals with weakened immune systems or underlying health conditions. The infection can involve various body sites, including the sinuses, lungs, skin, and gastrointestinal tract, and may progress rapidly if not treated promptly.

Causes

Zygomycosis is caused by fungi in the order Mucorales, which are commonly found in soil, decaying organic matter, and sometimes in hospital environments. Infection occurs when spores are inhaled, ingested, or enter the body through breaks in the skin. These fungi thrive in environments with high glucose levels, making them particularly dangerous for individuals with uncontrolled diabetes.

Risk Factors

• Uncontrolled diabetes mellitus, especially with diabetic ketoacidosis
• Weakened immune system (e.g., from chemotherapy, organ transplant, or HIV/AIDS)
• Prolonged corticosteroid use
• Skin trauma or burns
• Intravenous drug use
• Malnutrition or iron overload

Symptoms

• Sinusitis with black nasal discharge (in rhinocerebral cases)
• Fever, cough, and shortness of breath (in pulmonary cases)
• Skin lesions that may become necrotic or ulcerated
• Abdominal pain, nausea, or vomiting (in gastrointestinal cases)
• Headache, facial swelling, or vision changes (in rhinocerebral cases)

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT scans or MRI), and laboratory tests. Tissue samples are examined microscopically for characteristic fungal hyphae, and cultures may be performed to identify the specific organism. Blood tests and biopsies help assess the extent of infection and rule out other conditions.

Treatment Options

Treatment typically includes antifungal medications such as amphotericin B, often administered intravenously. Surgical debridement of infected tissue may be necessary to remove necrotic areas. Managing underlying conditions, such as controlling blood sugar in diabetic patients, is critical to improve outcomes.

Prognosis and Follow-Up

Prognosis depends on the site of infection, timeliness of treatment, and the patient’s overall health. Early intervention improves survival rates, but the infection can be fatal, especially in immunocompromised individuals. Follow-up care includes monitoring for recurrence and managing any residual health issues.

Complications

• Tissue necrosis and loss
• Spread of infection to the brain or other organs
• Organ failure
• Permanent disfigurement or functional impairment

Lifestyle & Prevention

• Maintain good hygiene and avoid contact with soil or decaying matter if immunocompromised.
• Control underlying conditions like diabetes.
• Seek prompt medical care for skin injuries or infections.
• Follow healthcare provider recommendations for immunosuppressive therapy management.

When to Seek Professional Help

Consult a healthcare provider immediately if you experience symptoms such as severe headache, facial swelling, black nasal discharge, or unexplained skin lesions, especially if you have a weakened immune system or diabetes.

Tips for Medical Coders

When coding for zygomycosis (B46), ensure documentation supports the specific site of infection (e.g., rhinocerebral, pulmonary) if reported. Note any underlying conditions like diabetes, as these may influence coding and reimbursement. Verify that the diagnosis is clearly documented to avoid denials.